T-1095

SGLT1和SGLT2抑制剂（IC50s分别为22.8和2.3µM）；饮食给药以0.01%w/w的剂量降低链脲佐菌素诱发的糖尿病大鼠模型中的血糖和HbA1c水平；抑制2型糖尿病KKAγ小鼠模型中的高血糖和高甘油三酯血症的发展并降低HbA1c水平；加剧左前降支冠状动脉结扎诱发的心肌梗死大鼠模型中的梗死后心脏功能障碍。An SGLT1 and SGLT2 inhibitor (IC50s = 22.8 and 2.3 µM, respectively); dietary administration reduces blood glucose and HbA1c levels in a rat model of streptozotocin-induced diabetes at 0.01% w/w; suppresses the development of hyperglycemia and hypertriglyceridemia and reduces HbA1c levels in the KKAγ mouse model of type 2 diabetes; exacerbates post-infarction cardiac dysfunction in a rat model of left anterior descending coronary artery ligation-induced myocardial infarction.分子式C26H28O11分子量516.5O=C(CCC1=CC=C(OC=C2)C2=C1)C(C(O)=CC(C)=C3)=C3O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)COC(OC)=O